Publications by authors named "Thomas Group"

Claim this Profile
I
Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine.
Nicola P Klein, Amy Wiesner, Oliver Bautista, Thomas Group, Kevin Kanu

Pediatrics· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types.
Katrina M Nolan, Brent Seaton, Joseph Antonello, Yuhua Zhang, Lauren Cook, Thomas Group

mSphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.
Ivette Maldonado, Manuel Plata, Mauricio Gonzalez, Alfonso Correa, Claudia Nossa, Thomas Group

Hum Vaccin Immunother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
Suzanne M Garland, Manjula Anagani, Neerja Bhatla, Sukanta Chatterjee, Sanjay Lalwani, Thomas Group

Hum Vaccin Immunother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
Huakun Lv, Shenyu Wang, Zhenzhen Liang, Wei Yu, Chuanfu Yan, Thomas Group

Vaccine· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Stephen E Goldstone, Anna R Giuliano, Joel M Palefsky, Eduardo Lazcano-Ponce, Mary E Penny, Thomas Group

Lancet Infect Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial.
Vu Dinh Thiem, Nguyen Dang Quang, Nguyen Hai Tuan, Kyeongmi Cheon, Nancy Gallagher, Thomas Group

Hum Vaccin Immunother· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up.
Susanne K Kjaer, Mari Nygård, Karin Sundström, Christian Munk, Sophie Berger, Thomas Group

Hum Vaccin Immunother· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
Zhuhang Huang, Jianfeng He, Jiali Su, Zhiqiang Ou, Guixiu Liu, Thomas Group

Vaccine· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries.
Susanne K Kjaer, Mari Nygård, Karin Sundström, Joakim Dillner, Laufey Tryggvadottir, Thomas Group

EClinicalMedicine· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
Alain Luxembourg, Susanne K Kjaer, Mari Nygard, Misoo C Ellison, Thomas Group

Contemp Clin Trials· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The puromycin-sensitive aminopeptidase PAM-1 is required for meiotic exit and anteroposterior polarity in the one-cell Caenorhabditis elegans embryo.
Rebecca Lyczak, Lynnsey Zweier, Thomas Group, Mary Ann Murrow, Christine Snyder

Development· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis